Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

about

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

Item

http://www.wikidata.org/entity/Q47146837

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

@en

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

@nl

type

Item

label

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

@en

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

@nl

prefLabel

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

@en

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

@nl

P1476

Older Patients With Acute Myeloid Leukemia: Treatment Challenges and Future Directions.

@en

P2093

Andrew Dalovisio

http://www.w3.org/2001/XMLSchema#string

James Foran

http://www.w3.org/2001/XMLSchema#string

Laura Finn

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Frailty in older adults: evidence for a phenotype

Cancer statistics, 2016

Early palliative care for patients with metastatic non-small-cell lung cancer

Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

P304

398-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29230125

http://www.w3.org/2001/XMLSchema#string

P932

5718453

http://www.w3.org/2001/XMLSchema#string